SCHEMBL4732712

SCHEMBL4732712

NC(=O)CSc1nc2sc3c(c2c(=O)n1C1CCCC1)CCCC3

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.68
▸ NPSR1 Q6W5P4 2/20 0.68
▸ SMN1; SMN2 Q16637 1/20 0.68
▸ KMT2A Q03164 6/20 0.59
▸ MEN1 O00255 5/20 0.59
▸ HPGD P15428 1/20 0.59
▸ HIF1A Q16665 1/20 0.59
▸ KDM4E B2RXH2 5/20 0.58
▸ MAPT P10636 3/20 0.58
▸ HTT P42858 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ ATM Q13315 1/20 0.57
▸ LMNA P02545 3/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ POLB P06746 1/20 0.53
▸ NR4A1 P22736 1/20 0.53
▸ APEX1 P27695 1/20 0.53
▸ APOBEC3A P31941 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13962176 0.88 ALDH1A1 (0.68) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079736 0.81 PDE4D (0.68) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079693 0.81 PDE4D (0.57) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079823 0.81 CREBBP (0.78) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079754 0.79 PDE4D (0.71) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079750 0.78 ALDH1A1 (0.73) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL20228784 0.75 KMT2A (0.85) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079825 0.70 CREBBP (0.63) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1
SCHEMBL19079844 0.69 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2KMT2AMEN1HPGD
SCHEMBL22533334 0.69 SMN1; SMN2 (0.71) ALDH1A1NPSR1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275586-A1 HETEROCYCLIC INHIBITORS OF PDE4 KALYPSYS, INC. (US) 2009-11-05 — — US disclosed
US-20090275586-A1 HETEROCYCLIC INHIBITORS OF PDE4 KALYPSYS, INC. (US) 2009-11-05 — — US disclosed
WO-2008045664-A2 HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS KALYPSYS, INC. (US) 2008-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275586-A1 HETEROCYCLIC INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 779/4885NPSR1 3204/4885SMN1; SMN2 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback